BiotechTube

Tinlarebant + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy

Trial Timeline

Jul 27, 2023 → Aug 31, 2027

NCT ID
NCT05949593

About Tinlarebant + Placebo

Tinlarebant + Placebo is a phase 3 stage product being developed by Belite Bio for Geographic Atrophy. The current trial status is active. This product is registered under clinical trial identifier NCT05949593. Target conditions include Geographic Atrophy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT06388083Phase 2/3Active
NCT05949593Phase 3Active
NCT05244304Phase 3Completed

Competing Products

20 competing products in Geographic Atrophy

See all competitors
ProductCompanyStageHype Score
avacincaptad pegolAstellas PharmaPhase 3
77
Avacincaptad PegolAstellas PharmaPhase 2/3
65
avacincaptad pegolAstellas PharmaApproved
85
Avacincaptad pegol (ACP)Astellas PharmaPre-clinical
23
Avacincaptad Pegol + ShamAstellas PharmaPhase 3
77
ABBV-6628 + SYFOVREAbbViePhase 1/2
41
FWY003 + PlaceboNovartisPhase 2
52
CLG561 + LFG316 + Sham injectionNovartisPhase 2
52
LFG316 + Sham + LFG316 Lower doseNovartisPhase 2
52
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
RO7669330 + Syfovre™ + Izervay™RochePhase 1
33
RO7303359RochePhase 1
33
SAR446597 + Sham ComparatorSanofiPhase 1/2
40
PozelimabRegeneron PharmaceuticalsPhase 1
32
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)Ionis PharmaceuticalsPhase 2
49
PegcetacoplanApellis PharmaceuticalsPre-clinical
18
APL-2 + APL-2Apellis PharmaceuticalsPhase 3
72
APL-2, PegcetacoplanApellis PharmaceuticalsPhase 3
72

Other Products from Belite Bio

Tinlarebant + PlaceboPhase 3
74
Tinlarebant + PlaceboPhase 2/3
62
tinlarebantPhase 1/2
38
BPN-14967 + PlaceboPhase 1
30
Tinlarebant (LBS-008)Phase 1
30